Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $131.86 Average Price Target from Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given a consensus rating of “Buy” by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $131.86.

LNTH has been the subject of several recent analyst reports. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th.

Lantheus Trading Down 2.0 %

Shares of Lantheus stock opened at $86.91 on Friday. The stock has a fifty day simple moving average of $92.02 and a 200 day simple moving average of $98.46. Lantheus has a 12-month low of $54.69 and a 12-month high of $126.89. The company has a market capitalization of $6.04 billion, a P/E ratio of 14.46 and a beta of 0.44.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Large investors have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus in the fourth quarter valued at approximately $27,000. Signaturefd LLC lifted its stake in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares in the last quarter. UMB Bank n.a. boosted its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. bought a new stake in Lantheus during the 3rd quarter valued at $51,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.